Afeletecan hydrochloride

N/A

Report date: 2022/10/14 20:00:43
NME

Base Information

Drug NameAfeletecan hydrochloride
Drug Alias NameBay-56-3722BAY-38-3441 (former code)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionDNA intercalatorsDNA topoisomerase inhibitors
TargetsDNADNA topoisomerase
Therapy Area/IndicationsSmall Cell Lung CarcinomaCarcinoma, Non-Small-Cell LungOvarian Neoplasms +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesBayer AG
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesNational Cancer InstituteBayer AG
Active IndicationsN/A
Inactive IndicationsSmall Cell Lung CarcinomaCarcinoma, Non-Small-Cell LungOvarian Neoplasms +[7] 

Other Information

ATC CodeN/A
Related LinksN/A